On Thursday, March 17, 2022, the U.S. Food and Drug Administration (FDA) approved the FoundationOne^®CDx to be used as a companion diagnostic to identify patients with non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) alterations and are appropriate for treatment with EGFR tyrosine kinase inhibitors that are approved by FDA for this indication.

Read Foundation Medicine's announcement.

Posted 3/17/2022